Seamus Mulligan, Director at Jazz Pharmaceuticals plc (JAZZ), sold 50,000 shares at $160.75 ($8.2M) on 2014-09-24, disclosed to the SEC on 2014-09-26.
Scheduled sale ($8.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $160.75 | 2,700 | $434K | 5.3% |
| 2 | $161.76 | 4,906 | $794K | 9.7% |
| 3 | $162.97 | 3,644 | $594K | 7.3% |
| 4 | $164.01 | 10,951 | $1.8M | 22.0% |
| 5 | $164.98 | 12,993 | $2.1M | 26.3% |
| 6 | $165.51 | 100 |
| $17K |
| 0.2% |
| 7 | $160.07 | 5,202 | $833K | 10.2% |
| 8 | $161.14 | 1,925 | $310K | 3.8% |
| 9 | $161.99 | 3,369 | $546K | 6.7% |
| 10 | $162.92 | 1,111 | $181K | 2.2% |
| 11 | $164.43 | 1,699 | $279K | 3.4% |
| 12 | $165.05 | 1,400 | $231K | 2.8% |
| Total | $163.16 avg | 50,000 | $8.2M | 100% |
| Filing → |
| JAZZ | BUY | 2018-11-19 | $14.2M | — | Filing → |
| JAZZ | SELL | 2016-08-26 | $6.0M | — | Filing → |
| JAZZ | SELL | 2016-05-26 | $8.2M | — | Filing → |